Ansaid patent extension
Executive Summary
Provision to extend the patent term of Upjohn's nonsteroidal anti-inflammatory drug by 5-1/2 years was deleted from Senate medical device legislation during the evening of Oct. 12. Sen. Metzenbaum (D-Ohio) supported the device law amendments (S 3006) but was determined to maintain a hold on the bill until the Ansaid provision was removed. S 3006 is now expected to proceed to the Senate floor by early in the week of Oct. 15.